Several studies have identified associations between single nucleotide polymorphisms (SNPs) occurring near the interleukin-28B (IL-28B) gene and response to antiviral treatment among hepatitis C virus (HCV) patients. Here, we describe a reliable melt-mismatch amplification mutation assay (melt-MAMA) PCR-based genotyping method for IL-28B which can be used in the management of HCV patients, helping to better define the course of therapy.Hepatitis C virus (HCV) is a positive-polarity, singlestranded RNA virus belonging to the genus Hepacivirus in the family Flaviviridae (12). Worldwide, an estimated of three million new infections occur annually and approximately 130 million people have been infected, the vast majority of infections becoming chronic infections (4). Moreover, a significant number of infected patients develop severe liver disease, including cirrhosis and hepatocellular carcinoma (7,9,17). Currently, the first line of HCV antiviral therapy is based on administration of pegylated alpha interferon (PEG-IFN-␣) and ribavirin (RBV). Unfortunately, this therapeutic strategy is effective only in around 50% of patients infected with HCV genotype 1,